Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

@article{Yanai2015LevelsOD,
  title={Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.},
  author={H Yanai and Lev Lichtenstein and Amit Assa and Yoav Mazor and Batia Weiss and Arie Levine and Yulia Ron and Uri Kopylov and Yoram Bujanover and Yoram Rosenbach and B Ungar and Rami Abraham Eliakim and Yehuda Chowers and Raanan Shamir and Gerald Fraser and Iris Dotan and Shomron Ben-Horin},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2015},
  volume={13 3},
  pages={522-530.e2}
}
BACKGROUND & AIMS There is controversy about whether levels of anti-tumor necrosis factor (TNF) and antidrug antibodies (ADAs) are accurate determinants of loss of response to therapy. We analyzed the association between trough levels of anti-TNF agents or ADAs and outcomes of interventions for patients with loss of response to infliximab or adalimumab. METHODS We performed a retrospective study of pediatric and adult patients with inflammatory bowel disease and suspected loss of response to… CONTINUE READING
68 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

Similar Papers

Loading similar papers…